https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>